Delay in award of tenders, higher entry barriers to new markets restricting growth: Kiran Mazumdar Shaw
The nature of these challenges is not linked to the fundamentals of the business: Biocon chief25-01-2021
25-01-2021
Biocon stock slides on poor Q3 results, exit of biologics arm's MD
From its previous close of Rs 441.95 apiece on Thursday, the stock closed 10.89 per cent or Rs 48.15 lower at Rs 393.80, on Friday23-01-2021
Earnings Call for Q3FY21 of Biocon Ltd.
Conference Call with Biocon Management and Analysts on Q3FY21 Performance and Outlook. Listen to the full earnings transcript.22-01-2021
Biocon Q3 net profit falls 17% to Rs 169 crore, revenue up 7%
The biosimilars and research services segment posted 11 per cent and 13 per cent growth, respectively, in their income during the quarter, while the generics business recorded a 3 per cent decline22-01-2021
Market reacts negatively to Biocon's weaker results, exit of biologics' MD
Analysts have raised doubts over the $1 billion guidance for biosimilars by FY22 and Hamacher's exit due to "professional differences"22-01-2021
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Q3FY21 Revenue at ? 1,879 Crore, Up 7%; EBITDA at ?427 Crore; Net Profit at ?169 Crore; Biosimilars up 11% at ?769 Crore; Research Services up 13% at ?585 Crore; Generics down 3% at ?561 Crore.21-01-2021
BIOCON LTD. - 532523 - Financial Results For The Quarter And Nine Months Ended December 31, 2020.
Dear Sir/Madam, Pursuant to Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirements) 2015, we wish to inform you that the Board of Directors at its meeting held today, has considered and approved the un-audited financial results (consolidated and standalone) as per Indian Accounting Standard (Ind-AS) along with Limited Review Report for the quarter and nine months ended December 31, 2020. A copy of the un-audited financial results along with the Limited Review Report is enclosed herewith. The above information will also be available on the website of the Company at www.biocon.com.21-01-2021
BIOCON LTD. - 532523 - Outcome Of Board Meeting
Dear Sir/Madam, Pursuant to Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirements) 2015, we wish to inform you that the Board of Directors at its meeting held today, has considered and approved the un-audited financial results (consolidated and standalone) as per Indian Accounting Standard (Ind-AS) along with Limited Review Report for the quarter and nine months ended December 31, 2020. A copy of the un-audited financial results along with the Limited Review Report is enclosed herewith. The above information will also be available on the website of the Company at www.biocon.com.21-01-2021
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director.21-01-2021
BIOCON LTD. - 532523 - Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 028280 Name of the Signatory :- Mayank VermaDesignation :- Company Secretary and Compliance Officer12-01-2021